Related Experiment Videos
[Risk and management of anti-vitamin K in the elderly]
1Unité gériatrique aiguë, hôpital Charles-Foix (AP-HP), Ivry-sur-Seine, France. eric.pautas@cfx.aphp.fr
Abstract:
VKA are underused in elderly patients with thrombo-embolic disease, mainly because of their increased risk of bleeding. However, in most cases, evaluation of this risk versus the efficacy in prevention of thrombo-embolic events, should not lead to a therapeutic abstention. The use of VKA in frail elderly patients requires a specific clinical assessment before and during treatment. Moreover, initiation and management of VKA therapy offers some specificities in older patients.
Related Concept Videos
Pharmacodynamics in Geriatric Patients: Effects of Age
Drug Dosing: Geriatric Patients
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Acute Kidney Injury IV: Diagnostic Studies and Prevention